-

TCGX Announces Oversubscribed $600 Million Asia Fund

New vehicle expands TCGX’s global investment platform with a dedicated focus on biotechnology companies based in Asia

SHANGHAI & PALO ALTO, Calif.--(BUSINESS WIRE)--TCGX today announced the closing of the TCGX Asia Life Sciences Fund I, an oversubscribed $600 million investment vehicle backed by a diverse group of international institutional investors. The fund will focus on investing in innovative biotechnology companies based in Asia.

In connection with the launch of TCGX Asia Life Sciences Fund I, L.P., TCGX is expanding its operations to Asia with new offices in Hong Kong and Shanghai to take advantage of the explosive growth of early-stage drug discovery in China.

Share

The fund is a new investment vehicle that will operate separately from, but in close synergy with, TCGX’s Flagship Funds, which focus on biotechnology companies in the United States and Europe. Together, the funds will allow TCGX to identify and support differentiated biotechnology companies across the world while maintaining dedicated investment teams and regional focus.

The fund reflects TCGX’s conviction in the growing breadth and quality of biotechnology innovation across Asia and will invest across stages of company development, partnering with entrepreneurs and management teams developing differentiated medicines for patients globally.

“Asia has become an increasingly important source of globally competitive biotechnology innovation,” said Dr. Chen Yu, Founder and Managing Partner of TCGX. “We believe there is a significant opportunity to partner with exceptional entrepreneurs and scientists across the region who are building companies capable of developing transformative medicines for patients worldwide. The Asia Fund gives us a dedicated platform to pursue these opportunities while leveraging the broader capabilities and network of TCGX.”

In connection with the launch of the fund, TCGX is expanding its operations to Asia, with new offices in Shanghai and Hong Kong.

“We are seeing exceptional growth in the quality of science, entrepreneurial talent, and company formation across the Asian biotechnology ecosystem,” said Dandan Dong, Managing Partner of TCGX in Asia. “Our goal is to partner with the most promising biotechnology companies in the region and bring TCGX’s investment experience, scientific expertise, and global network to help them realize their potential on a global scale.”

The closing of the fund expands TCGX’s ability to invest behind compelling science across the world while maintaining distinct regional investment strategies.

About TCGX

TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that improve the lives of patients. TCGX invests in private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. The firm’s Flagship Funds invest in biotechnology companies in the United States and Europe, while the TCGX Asia Life Sciences Fund I is focused on biotechnology companies based in Asia.

TCGX has offices in Palo Alto, San Francisco, New York City, Shanghai, and Hong Kong.

Contacts

Edward Amorosi
M: +1.917.514.0242
E: eamorosi@tcgcrossover.com

More News From TCGX

TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX) (“TCGX”), a publicly listed special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) to the U.S. Securities and Exchange Commission (“SEC”). The submission of the Re...

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”...

TCGX Acquisition Corp. II Announces Pricing of $100,000,000 Initial Public Offering

PALO ALTO, Calif.--(BUSINESS WIRE)--TCGX Acquisition Corp. II (the “Company”) announced today that it priced its initial public offering of 10,000,000 Class A ordinary shares at a price of $10.00 per share, for gross proceeds of $100,000,000. Unlike certain other special purpose acquisition company initial public offerings, investors in this offering will not receive warrants that would become exercisable following the completion of the Company’s initial business combination.The Class A ordinary...
Back to Newsroom